<DOC>
	<DOCNO>NCT02025205</DOCNO>
	<brief_summary>The aim prospective , randomize , control , one-way crossover study ass compare efficacy Zephyr endobronchial valve vs. Standard Care ( SoC ) patient suffer COPD Homogeneous Emphysema . Patients follow 12 month randomization . Patients SoC arm crossover EBV treatment arm 6-month visit follow 6 additional months.The primary objective variation FEV1 baseline 3-month follow-up visit . The secondary objective evaluate quality life , exercise capacity , dyspnea ( include BODE index ) change , target lobe volume reduction , well safety outcome .</brief_summary>
	<brief_title>Improving Patient Outcomes Selective Implantation Zephyr EBV - Study</brief_title>
	<detailed_description />
	<mesh_term>Emphysema</mesh_term>
	<mesh_term>Pulmonary Emphysema</mesh_term>
	<criteria>Homogeneous emphysema 15 % &lt; = FEV1 &lt; = 45 % predict TLC &gt; 100 % predict RV &gt; = 200 % predict 6MWT &gt; = 150 Nonsmoker &gt; 8 week prior study entry Absence Collateral Ventilation target lobe Active pulmonary infection More 3 exacerbation hospitalization past 12 month Pulmonary hypertension ( sPAP &gt; 45 mmHg ) MI relevant CV event past 6 month Alpha1 antitrypsin deficiency Bronchiectasis Prior LVR LVRS procedure &gt; 20 % difference perfusion right leave lung Hypercapnia ( paCO2 &gt; 55 mmHg Asthma Use 25 mg/day prednisolone equivalent Severe bullous emphysema Systemic malignant disease high death probability within 12 month</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>